Document 6bzGpQ7bz8Ny1Rvpb1rZdn0Md

To: From: Cc: Bcc: Received Date: Subject: Cagen, Stuart Z SCC-HSE <stuart.cagen@shell.com> Beatty, Patrick (PatrickBeatty) <PatrickBeatty@chevrontexaco.com> Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com> 2003-10-01 14:40:56 GMT RE: SHS Thanks. This clearly an area where we can cut back if necessary. Patrick -----Original Message----From: Cagen, Stuart Z SCC-HSE [mailto:stuart.cagen@shell.com] Sent: Tuesday, September 30,200311 :29 PM To: Beatty, Patrick (PatrickBeatty) Cc: Clegg, Patsy M SCC-CHSE-PC Subject: SHS Patrick: For what it is worth, note the recent benzene biomarker study used much less than 2000 individuals to characterize dose response of benzene biomarkers - see http://www.healtheffects.org/Pubs/Qu.pdf In addition, a companion HEI study with 1,3 butadiene used only 83 workers and was effective in showing dose response of butadiene exposure with biomarkers and lack of biomarkers of effect - see http://www.healtheffects.org/PubS/Albertini.pdf Stuart Stuart Cagen Shell Chemical LP One Shell Plaza, 91 0 Louisiana, Houston, TX 77002-4916 Tel: +1 713241 1407 Fax: +1 713241 3325 Other Tel: +1 8326463987 Email: stuart.cagen@shell.com Internet: http://www.shell.com/chemicals SH ELL-MCCLU RG-055770